ArticleDiscover nano2024
Zinc oxide and copper oxide nanoparticles as a potential solution for controlling Phytophthora infestans, the late blight disease of potatoes.
Article in Discover nano, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- PhytoSynthesized Nano-Zinc Formulation for Sustainable Growth and Yield Enhancement in Tomatoes Under Protected Cultivation.Plants (Basel, Switzerland) · 2026Article
- Rhizospheric Microbes and Nanoparticles Synergize to Enhance Plant Immune Responses.Plant-environment interactions (Hoboken, N.J.) · 2026Review
- Phytotoxic and Eustress Effects of Metal Oxide Nanoparticles (CuO, MnPlants (Basel, Switzerland) · 2026Review
- Smart nanosystems for disease-resistant potatoes: a new Frontier in nanobiotechnology.RSC advances · 2026Review
- Nanotechnology-driven strategies to overcome azole resistance inFrontiers in plant science · 2026Review
- Green synthesis of demethoxycurcumin-loaded chitosan nanoparticles for the management of potato late blight caused by Phytophthora infestans.International journal of biological macromolecules · 2025Article
- Plant-Based ZnO Nanoparticles for Green Nanobiocontrol of a Highly Virulent Bacterial Leaf Blight Pathogen: Mechanistic Insights and Biocompatibility Evaluation.Nanomaterials (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Late blight, caused by Phytophthora infestans, is a major potato disease globally, leading to significant economic losses of $6.7 billion. To address this issue, we evaluated the antifungal activity of ZnO and CuO nanoparticles (NPs) against P. infestans for the first time in laboratory and greenhouse conditions. Nanoparticles were synthesized via a chemical precipitation method and characterized using various techniques. The XRD results revealed that the synthesized ZnO nanoparticles had a pure hexagonal wurtzite crystalline structure, whereas the CuO NPs had a monoclinic crystalline structure. TEM images confirmed the synthesis of quasi-spherical nanoparticles with an average size of 11.5 nm for ZnO NPs and 24.5 nm for CuO NPs. The UV-Vis Spectral Report showed peaks corresponding to ZnO NPs at 364 nm and 252 nm for CuO NPs.In an in vitro study, both ZnO and CuO NPs significantly (p < 0.05) inhibited the radial growth of P. infestans at all tested concentrations compared to the untreated control. The highest inhibitory effect of 100% was observed with ZnO and CuO NPs at 30 mg/L. A lower inhibition of 60.4% was observed with 10 mg/L CuO NPs. Under greenhouse conditions, 100 mg/L ZnO NPs was the most effective treatment for controlling potato late blight, with an efficacy of 71%. CuO NPs at 100 mg/L followed closely, with an efficacy of 69%. Based on these results, ZnO and CuO NPs are recommended as promising eco-friendly fungicides for the management and control of potato late blight after further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.